Intake of Antacids improves blood sugar control in diabetes patients: Study

Researchers at University of Maryland School of Medicine in Baltimore and Hualien Tzu Chi Hospital in Hualien, Taiwan have found in a new Systematic Review and Meta-analysis, that proton pump inhibitors improved blood sugar control in diabetes patients. However they had no effect on reducing the risk of diabetes in the general population.Therefore the effects of PPI on glycemic control should be considered when prescribing antacids to patients with diabetes.

The new meta-analysis has been published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

"Our research demonstrated that prescribing antacids as an add-on to standard care was superior to standard therapy in decreasing hemoglobin A1c (HbA1c) levels and fasting blood sugar in people with diabetes," said study author Carol Chiung-Hui Peng, M.D., of the University of Maryland Medical Center Midtown Campus in Baltimore, Md.

"For people without diabetes, taking antacids did not significantly alter their risk of developing the disease," said study author, Huei-Kai Huang M.D., of the Hualien Tzu Chi Hospital in Hualien, Taiwan.

The researchers performed a meta-analysis on the effects of proton pump inhibitors (PPIs)--a commonly used type of antacid medication--on blood sugar levels in people with diabetes and whether these medications could prevent the new onset of diabetes in the general population. The analysis included seven studies (342 participants) for glycemic control and 5 studies (244, 439 participants) for risk of incident diabetes. The researchers found antacids can reduce HbA1c levels by 0.36% in people with diabetes and lower fasting blood sugar by 10 mg/dl based on the results from seven clinical trials. For those without diabetes, the results of the five studies showed that antacids had no effect on reducing the risk of developing diabetes.

"People with diabetes should be aware that these commonly used antacid medications may improve their blood sugar control, and providers could consider this glucose-lowering effect when prescribing these medications to their patients," said study author Kashif Munir, M.D., associate professor in the division of endocrinology, diabetes and nutrition at the University of Maryland School of Medicine in Baltimore, Md.

Other authors of the study include: Yuting Huang and Khulood Bukhari of the University of Maryland Medical Center Midtown Campus in Baltimore, Md.; Yu-Kang Tu of the National Taiwan University and the Taipei Medical University in Taipei, Taiwan; Gin Yi Lee of the Danbury Hospital in Danbury, Conn.; Rachel Huai-En Chang of the Johns Hopkins Bloomberg School of Public Health in Baltimore, Md.; Yao-Chou Tsai of the Taipei Medical University; Yunting Fu of the University of Maryland in Baltimore, Md.

For further reference log on to:

The Journal of Clinical Endocrinology & Metabolism, dgab353, https://doi.org/10.1210/clinem/dgab353